Aidoc launches the first ai-based automated notification solution for high-risk pulmonary embolism patients
The workflow-integrated solution developed in collaboration with Yale radiologists expedites time-sensitive decision-making and improves quality of care.
Aidoc, the leading provider of enterprise AI solutions, announced today the launch of an industry first: an AI-based automated activation solution that facilitates rapid risk assessment and care coordination for high-risk pulmonary embolism (PE) patients.
Aidoc’s PE Care Coordination includes Aidoc’s FDA-cleared solution for triage and notification of PE. The solution is “Always-on”, running behind the scenes and does not require physician activation. High-risk PE patients are automatically flagged after the scan is performed and a notification is sent simultaneously to all the relevant team members, including radiologists, pulmonologists, cardiologists and vascular surgeons. Once the teams are alerted, the solution enables real-time image, data and text sharing leading to improved patient management and care coordination.
The launch is part of an ongoing Aidoc partnership with the Department of Radiology and Biomedical Imaging at Yale School of Medicine and follows six months of clinical use led by the Yale radiology team.
“We have been using the first version of this solution for the last six months and have seen the real impact this has had on addressing patients that require treatment beyond anticoagulation,” said Dr. Irena Tocino, Professor and Vice Chair of Medical Informatics in the department of Radiology & Biomedical Imaging at Yale School of Medicine (YSM). “Having this subset of patients routed simultaneously to multiple stakeholders has shown a reduction in time to treatment and clear improvements in patient outcomes.”
“The PE Response Team (PERT) was established to provide rapid risk assessment along with execution of the patient management strategy,” said Dr. Akhil Khosla, co-director of the PERT program, in the department of Internal Medicine at YSM. “One of the challenges of establishing a PERT program is making sure the right information is in the hands of the right clinician. In Aidoc, we have a partner with the ability to bring deep integration of AI into these native workflows. The outcome leads to enhanced patient eligibility for novel therapies and makes a significant change to patient management.” PE outcomes are highly variable. While some patients have excellent prognosis without any treatment, others may require invasive and urgent therapies. Rapid risk assessment of acute PE cases is essential for the triage of patients, and a multidisciplinary approach to patient treatment and management can be the defining factor in their care.
Related news
-
Bayer driving innovation in radiology with new research across the portfolio presented at ECR
Featured presentations include development compound gadoquatrane, a novel contrast agent for MRI Further research explores potential of AI and digital advances in medical imaging Bayer announced today that new data from the company’s advanced radiology portfolio will be presented at the 2023 European Congress of Radiology (ECR), taking place from March 1-5 in Vienna, Austria. The presentations reflect Bayer’s commitment as a leading company in key radiology areas to accelerate innovation for the...
-
Bayer completes acquisition of Blackford Analysis Ltd.
Closing follows announcement of acquisition on January 18, 2023 Acquisition bolsters Bayer’s position in digital medical imaging Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today announced that the company has completed the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. As a result, Blackford, which has a presence in the United...
-
Ultravist by Bayer now approved for contrast-enhanced mammography in EU
Ultravist-300, -370 receives green light for indication extension for use in contrast-enhanced mammography (CEM) in a European Workshare Procedure CEM is emerging modality combining digital mammography with the administration of a contrast agent Strategically expands Bayer’s portfolio in breast imaging, including contrast agents and injectors Bayer announced today that its iodine-based contrast agent Ultravist™-300, -370 is now approved for contrast-enhanced mammography (CEM) in the EU. The...
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. The...
-
Inspirata Accelerates Its Growth as a Leading Provider of AI/NLP Technology in Oncology Informatics
Inspirata Inc. and FUJIFILM Corporation signed an asset purchase agreement for Fujifilm to acquire Inspirata’s Dynamyx® digital pathology technology, employees and customers, building off the proven success of the established partnership between the companies in UK and Europe. This milestone allows the Digital Pathology business to flourish with a partner who has the breadth, depth and resources required to take the Dynamyx platform to the next stage of its growth and international expansion. The...
Customer comments
No comments were found for Aidoc launches the first ai-based automated notification solution for high-risk pulmonary embolism patients. Be the first to comment!